

08/15/01
U.S. PTO
RECEIVED

08/16/01

A

Docket Number 4-30811A/C1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 751039764 US
Express Mail Label Number

August 15, 2001
Date of Deposit

jc971 U.S. PTO
08/15/01
08/15/01
08/15/01

Address to: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) (1) is a continuation of prior Application No. PCT/EP00/01196, filed February 14, 2000.

Applicant (or identifier): MATTHEWS ET AL.

Title: SPONTANEOUSLY DISPERSIBLE N-BENZOYL STAUROSPORINE COMPOSITIONS

Enclosed are:

1. Specification (Including Claims and Abstract) - 23 pages
2. Drawings - 3 sheets
3. Non-executed Declaration and Power of Attorney (original or copy)
4. Microfiche Computer Program (appendix)
5. Nucleotide and/or Amino Acid Sequence Submission
 - Computer Readable Copy
 - Paper Copy
 - Statement Verifying Identity of Above Copies
6. Preliminary Amendment
7. Assignment Papers (Cover Sheet & Document(s))
8. English Translation of
9. Information Disclosure Statement
10. Certified Copy of Priority Document(s)
11. Return Receipt Postcard
12. Other: Application Data Sheet

Filing fee calculation:

Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
 Before calculating the filing fee, please cancel claims

Basic Filing Fee							\$ 710
Multiple Dependent Claim Fee (\$ 270)							\$
Foreign Language Surcharge (\$ 130)							\$
	For	Number Filed		Number Extra		Rate	
Extra Claims	Total Claims	13	-20	0	x	\$ 18	= \$
	Independent Claims	4	-3	1	x	\$ 80	= \$ 80
TOTAL FILING FEE							\$ 790

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$790. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
 Novartis Corporation
 Patent and Trademark Dept.
 564 Morris Avenue
 Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Respectfully submitted,

Date: August 14, 2001

Norbert Gruenfeld
 Norbert Gruenfeld
 Agent for Applicants
 Reg. No. 30,061
 Tel. No. (908) 522-6921